These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24282979)

  • 1. Triple-negative breast cancer: not entirely negative.
    Leone JP; Puhalla S
    Oncology (Williston Park); 2013 Sep; 27(9):856, 858-9. PubMed ID: 24282979
    [No Abstract]   [Full Text] [Related]  

  • 2. Triple-negative breast cancer in the post-genomic era.
    Williams N; Harris L
    Oncology (Williston Park); 2013 Sep; 27(9):859-60, 864. PubMed ID: 24282980
    [No Abstract]   [Full Text] [Related]  

  • 3. Androgen receptor-positive, triple-negative breast cancer.
    Gucalp A; Traina TA
    Cancer; 2017 May; 123(10):1686-1688. PubMed ID: 28406524
    [No Abstract]   [Full Text] [Related]  

  • 4. Notch inhibitors and their role in the treatment of triple negative breast cancer: promises and failures.
    Locatelli M; Curigliano G
    Curr Opin Oncol; 2017 Nov; 29(6):411-427. PubMed ID: 28914645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targets of triple-negative breast cancer: a review.
    Jamdade VS; Sethi N; Mundhe NA; Kumar P; Lahkar M; Sinha N
    Br J Pharmacol; 2015 Sep; 172(17):4228-37. PubMed ID: 26040571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New targets for triple-negative breast cancer.
    Herold CI; Anders CK
    Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular pathways: PI3K pathway targets in triple-negative breast cancers.
    Gordon V; Banerji S
    Clin Cancer Res; 2013 Jul; 19(14):3738-44. PubMed ID: 23748695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical research on triple-negative breast cancer that targets the PIK3CA pathway.
    Altundag K
    Med Oncol; 2024 Oct; 41(11):268. PubMed ID: 39400773
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?
    Jacot W; Theillet C; Guiu S; Lamy PJ
    Future Oncol; 2015; 11(4):557-9. PubMed ID: 25686112
    [No Abstract]   [Full Text] [Related]  

  • 10. Molecular mechanism of anti-cancer activity of phycocyanin in triple-negative breast cancer cells.
    Ravi M; Tentu S; Baskar G; Rohan Prasad S; Raghavan S; Jayaprakash P; Jeyakanthan J; Rayala SK; Venkatraman G
    BMC Cancer; 2015 Oct; 15():768. PubMed ID: 26499490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of targeted therapies in the treatment of triple-negative breast cancer.
    Jia LY; Shanmugam MK; Sethi G; Bishayee A
    Anticancer Drugs; 2016 Mar; 27(3):147-55. PubMed ID: 26682525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K; Le A; Weaver VM; Werb Z
    Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the androgen receptor in triple-negative breast cancer.
    Gucalp A; Traina TA
    Curr Probl Cancer; 2016; 40(2-4):141-150. PubMed ID: 27816190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicine for the treatment of triple-negative breast cancer.
    Kutty RV; Wei Leong DT; Feng SS
    Nanomedicine (Lond); 2014 Apr; 9(5):561-4. PubMed ID: 24827837
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
    Denkert C; Liedtke C; Tutt A; von Minckwitz G
    Lancet; 2017 Jun; 389(10087):2430-2442. PubMed ID: 27939063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple Negative Breast Cancer: A Tale of Two Decades.
    Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
    Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.
    Ocana A; Pandiella A
    Oncotarget; 2017 Mar; 8(13):22218-22234. PubMed ID: 28108739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned.
    Santa-Maria CA; Gradishar WJ
    JAMA Oncol; 2015 Jul; 1(4):528-34; quiz 549. PubMed ID: 26181262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Checkpoint inhibitors in breast cancer: hype or promise?
    McArthur HL
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):392-5. PubMed ID: 27379806
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.